RxDoctor Payments Data

Susanne Bodine, APRN

Nurse Practitioner · Covington, KYNPI 1538417399

Payments from drug & device makers

$7,105in general payments, 2019–2025

Across 324 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Dexcom, Inc.$910
  • Lilly USA, LLC$766
  • Corcept Therapeutics$497
  • Abbott$424
  • Sanofi-aventis U.S. LLC$298
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$7,094100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,105 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$59,030
Medicare patients
233
Services billed
1,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide239$357,731
TrulicityDulaglutide109$182,535
JardianceEmpagliflozin104$145,061
Tresiba Flextouch U-100Insulin Degludec107$79,061
MounjaroTirzepatide55$76,390
FarxigaDapagliflozin Propanediol68$75,207
Repatha SureclickEvolocumab67$67,400
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog86$64,023
Tresiba Flextouch U-200Insulin Degludec56$62,308
Lantus SolostarInsulin Glargine,hum.Rec.Anlog326$61,150
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog41$55,037
Novolog FlexpenInsulin Aspart144$42,691
Humulin R U-500 KwikpenInsulin Regular, Human14$39,777
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog51$37,835
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/719$31,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$1,279$375,854293 claims
Lilly USA, LLCTrulicity, Mounjaro$766$258,926164 claims
Boehringer IngelheimJardiance$100$145,061104 claims
AstraZenecaFarxiga$272$75,20768 claims
Sanofi-aventis U.S. LLCLantus$298$8,45736 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$3,097233 claims
AbbVieSynthroid$230$1,43130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Covington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →